MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
sale of common stock
$237,033,938
Proceeds from exercise of
stock awards and...
$11,858,358
Proceeds from sales and
maturities of marketable...
$260,595,875
Net cash provided by
financing activities
$248,892,296
Net cash provided by
(used in) investing...
$97,479,281
Canceled cashflow
$163,116,594
Net increase
(decrease) in cash and cash...
$276,560,316
Canceled cashflow
$69,811,261
Purchase of marketable
securities
$151,392,398
Payments for
construction in progress
$8,436,196
Purchases of property and
equipment
$2,904,461
Payments for leasehold
improvements
$383,539
Stock-based compensation
$16,967,799
Receivables
-$10,309,322
Accounts payable and
accrued expenses
$5,983,992
Non-cash interest
expense on cirm...
$3,045,725
Depreciation and
amortization
$1,889,041
Changes in lease
liabilities
$715,459
Restricted stock awards
granted
$257,461
Loss on disposal of
fixed assets
-$157,519
Net cash used in
operating activities
-$69,811,261
Canceled cashflow
$39,326,318
Net loss
-$105,043,946
Prepaid expenses and
other assets
$4,093,633
Back
Back
Cash Flow
source: myfinsight.com
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)